Spherix Incorporated , an intellectual property company, owns, develops, acquires, and monetizes patented and unpatented intellectual properties. The company owns approximately 290 patents and patent applications. Its patent portfolio includes the U.S. and foreign patents and pending patent applications in the wireless communications and telecommunication sectors, including data, optical and voice technology, antenna technology, Wi-Fi, base station functionality, and cellular. Spherix Incorporated was founded in 1967 and is based in New York, New York.

  • Spherix Issues Update to Shareholders
    on October 21, 2019 at 12:30 pm

    NEW YORK, Oct. 21, 2019 /PRNewswire/ -- Spherix Incorporated (SPEX) President and CEO, Anthony Hayes, today released a letter to shareholders outlining the Company's plans for its previously disclosed dividend distribution. As we accelerate our transformation into an innovative biotech company, I believe this is the optimal time to provide our shareholders with a detailed update.  I am excited at the potential for Spherix and believe we have put several important pieces in place to drive future success. First, October 21, 2019 is the record date for our dividend distribution.  If you are a shareholder of record at 5 p.m. Eastern Standard on that date, you will receive one share of Hoth Therapeutics, Inc common stock for every 29 shares of Spherix common stock you own.  The distribution of the Hoth shares is currently anticipated to occur on or about October 28, 2019, subject to effectiveness of the registration statement for such shares.

  • Spherix Highlights ValuEngine Upgrade to 'Buy' Rating
    on October 17, 2019 at 12:30 pm

    NEW YORK , Oct. 17, 2019 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that its stock has been upgraded to a "buy" rating from a "hold" rating in a research note ...

  • Emerging Markets Report: In the Money
    on October 16, 2019 at 3:13 pm

    It is not often in the pages of the Emerging Markets Report do we get the opportunity to tell our readers that a Company is giving back roughly $425,000* worth of value to its shareholders. Every Spherix stockholder will be entitled to receive one share of Hoth common stock for every twenty-nine shares of Spherix common stock held as of 5 p.m. Eastern Time on October 21, 2019. Extrapolating from that model, ten thousand shares of Spherix at a cost basis of $16,900 earns the owner 344 Hoth shares worth $1,482 on paper.

  • Spherix Sets Record Date for Dividend Distribution
    on October 11, 2019 at 6:15 pm

    NEW YORK, Oct. 11, 2019 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that on October 2, 2019, the Board of Directors of Spherix Incorporated ("Spherix") approved a distribution to Spherix stockholders of 100,000 shares of Hoth Therapeutics, Inc. ("Hoth") held by Spherix. Each Spherix stockholder will be entitled to receive one (1) share of Hoth common stock for every twenty-nine (29) shares of Spherix common stock held as of 5 p.m. Eastern Time on October 21, 2019, the record date.

  • Emerging Markets Report: Botox, Anthrax, and the Healing Power of Poison
    on October 2, 2019 at 11:00 am

    When Botox hit the annals of pop culture as a beauty product, a healer, and more it was shocking to many. Today it appears that deadly Anthrax may be breaking good as Botox has, intent on joining the ranks of the helpful and the healers while eschewing its well-earned infamy for contributing to the actual Fall of Rome and more recently, a domestic bio-terrorism event that had the nation on edge. Indeed, U.S. based Spherix Inc. (SPEX) believes that Anthrax could very well be used to effectively fight ovarian cancer.

  • Spherix Issues Update to Shareholders Regarding Planned Dividend Distribution
    on September 25, 2019 at 5:30 pm

    NEW YORK, Sept. 25, 2019 /PRNewswire/ -- Spherix Incorporated (SPEX) President and CEO, Anthony Hayes, today released a letter to shareholders outlining the Company's plans for its previously disclosed dividend distribution. As previously stated, Spherix is moving forward with the distribution of 100,000 shares of common stock of Hoth Therapeutics, Inc. to its shareholders. Spherix's Board of Directors will meet to set a record date for the stock dividend.

  • University of Maryland, Baltimore Grants Spherix Exclusive Option to License Anthrax Based Ovarian Cancer Drug PrAg-PAS
    on September 17, 2019 at 5:30 pm

    The Option includes rights to U.S. Patent Application Serial No. 15/747,255, which is currently under active examination at the U.S. Patent and Trademark Office.  Under the Option, Spherix has until early December of 2019 to complete its due diligence and execute a license agreement for commercial development.

  • Spherix is Granted Exclusive Option to License Anticancer Drug from the University of Kentucky
    on September 11, 2019 at 5:00 pm

    NEW YORK, Sept. 11, 2019 /PRNewswire/ -- Spherix Incorporated (SPEX) today announced that the Company has executed an exclusive option agreement ("Option") with the University of Kentucky (UK) related to its anticancer drug designated G4-1, a novel proteasome inhibitor. Spherix's Option includes two issued patents, United States Patent Nos. Under the Option, Spherix has until late November to complete its due diligence and execute a license agreement for commercial development.

  • Spherix Announces Results of Special Meeting of Shareholders
    on September 9, 2019 at 12:00 pm

    At the Meeting, the Company's shareholders approved the issuance of shares of our Common Stock, including shares of our common stock underlying Series L convertible preferred stock, to be issued by us pursuant to the terms of that certain Asset Purchase Agreement, dated May 15, 2019, by and between the Company and CBM BioPharma, Inc., as amended by Amendment No. 1 to the Asset Purchase Agreement, dated May 30, 2019, in an amount equal to or in excess of 20% of our common stock outstanding before the issuance of such common stock and such Series L convertible preferred stock (including upon the operation of anti-dilution provisions contained in such Series L convertible preferred stock). Shareholders also approved the amendment to the Company's Amended and Restated Certificate of Incorporation to decrease the number of authorized shares of common stock from 100,000,000 to 99,000,000.

  • Spherix Urges Shareholders to Approve Purchase of CBM BioPharma, Inc. Assets at Special Meeting
    on August 19, 2019 at 12:00 pm

    In advance of our Special Meeting on September 5th, I write to update you on certain developments and to encourage you to vote in favor of the proposals recommended by the Board of Directors and set forth in the Special Meeting Proxy. The acquisition of the CBM BioPharma, Inc. ("CBM") pharmaceutical assets is an integral step in building Spherix into a cutting edge pharmaceutical company.  It also builds upon the success we have already realized as a part of the Company's transformation.  Two years ago, Spherix made an investment in Hoth Therapeutics, Inc., which is now estimated to be worth over $10,000,000.  In our effort to deliver value to our shareholders and to continue the transformation at Spherix, the Board intends to propose a special dividend of One Hundred Thousand shares (100,000) of Hoth stock.

Did you get a chance to watch this yet? https://finance.yahoo.com/news/spherix-provides-video-demonstration-cbm-120000928.html

@spherixinc, a patent commercialization co., names Dr. Tom Wilkie, Associate Prof at the University of Texas Southwestern Medical Center, as Chief Science Officer

For even more info on CBM BioPharma and our new direction, please visit CBM's website: http://www.cbmbiopharmainc.com

We are so excited to announce our merger with CBM BioPharma, Inc! For more information, please check: https://finance.yahoo.com/news/spherix-merge-cbm-biopharma-pharmaceutical-120000752.html

Load More...

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

Spherix Incorporated

One Rockefeller Plaza
11th Floor
New York, NY 10020

+1 (703) 992-9325

www.spherix.com

November 2019
S M T W T F S
« Oct    
 12
3456789
10111213141516
17181920212223
24252627282930

©2019 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account